Cargando…

Systematic literature reviews over the years

Purpose: Nowadays, systematic literature reviews (SLRs) and meta-analyses are often placed at the top of the study hierarchy of evidence. The main objective of this paper is to evaluate the trends in SLRs of randomized controlled trials (RCTs) throughout the years. Methods: Medline database was sear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smela, Beata, Toumi, Mondher, Świerk, Karolina, Gawlik, Konrad, Clay, Emilie, Boyer, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443963/ https://www.ncbi.nlm.nih.gov/pubmed/37614556 http://dx.doi.org/10.1080/20016689.2023.2244305

Ejemplares similares

Rapid literature review: definition and methodology
por: Smela, Beata, et al.
Publicado: (2023)

Characteristics of doctor-shoppers: a systematic literature review
por: Biernikiewicz, Małgorzata, et al.
Publicado: (2019)

Health related quality of life in patients having schizophrenia negative symptoms – a systematic review
por: Azaiez, Chiraz, et al.
Publicado: (2018)

Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries
por: Clay, Emilie, et al.
Publicado: (2012)

Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
por: Clay, Emilie, et al.
Publicado: (2019)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

The quality of life of Spanish patients with Huntington's disease measured with H-QoL-I and EQ-5D
por: Dorey, Julie, et al.
Publicado: (2016)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe
por: Monleón, Clara, et al.
Publicado: (2022)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Benefits of probabilistic sensitivity analysis – a review of NICE decisions
por: Adalsteinsson, Erpur, et al.
Publicado: (2013)

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC
por: Siani, Carole, et al.
Publicado: (2015)

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis
por: Wojciechowski, Piotr, et al.
Publicado: (2021)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies
por: Dabbous, Omar, et al.
Publicado: (2022)

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update
por: Han, Ru, et al.
Publicado: (2019)

Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis
por: Millier, Aurelie, et al.
Publicado: (2011)

Economic and health implications from earlier detection of HIV infection in the United Kingdom
por: Zah, Vladimir, et al.
Publicado: (2016)

Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis
por: Moćko, Paweł, et al.
Publicado: (2016)

Value added medicines: what value repurposed medicines might bring to society?
por: Toumi, Mondher, et al.
Publicado: (2016)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

The Market Access Society launches a new journal
por: Toumi, Mondher
Publicado: (2013)

Factors influencing the COVID-19 daily deaths' peak across European countries
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Impact of the COVID-19 pandemic on the conduct of clinical trials: a quantitative analysis
por: Margas, Wojciech, et al.
Publicado: (2022)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Gene therapy randomised clinical trials in Europe – a review paper of methodology and design
por: Ilieva, Krassimira, et al.
Publicado: (2020)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)

New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014)

Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
por: Jarosławski, Szymon, et al.
Publicado: (2011)

Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis
por: Toumi, Mondher, et al.
Publicado: (2014)

National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning
por: Ricciardi, Walter, et al.
Publicado: (2015)

Introduction
por: Toumi, Mondher, et al.
Publicado: (2015)

Non-profit drug research and development: the case study of Genethon
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Advanced therapy medicinal products: current and future perspectives
por: Hanna, Eve, et al.
Publicado: (2016)

Market access pathways for cell therapies in France
por: Rémuzat, Cécile, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kqfum0g2bhtbut0jsfgagjv53f